The Wolfson Institute for Biomedical Research
at the Cruciform Building

Business Development

Spin-out Companies

Spin-out companies from the WIBR have raised in the region of £100 million in venture capital. Income has been realised from sale of shares after public listings and from trade sales. Ark Therapeutics, which develops therapeutics for vascular disease and cancer, was floated on the London Stock Exchange in 2004. Arrow Therapeutics, NCE Discovery, Inpharmatica, and CereXus have all achieved successful exits through acquisitions and trade sale.

Ark Therapeutics

Ark Therapeutics Group plc is a specialist healthcare group focused on vascular disease, wound care and cancer. It is marketing four medical products (Kerraboot®, Kerraped®, Neuropad®, and Flaminal®), and three of its lead pharmaceutical products (Cerepro®, Vitor™ and Trinam®) are in phase III clinical development.

Web: www.arktherapeutics.com

Ark Therapeutics

Arrow Therapeutics

Arrow Therapeutics Ltd. is a London-based pharmaceutical company focused exclusively on research and development of novel antiviral drugs. Its in-house research has resulted in compounds active against hepatitis C and respiratory syncytial virus. In 2007 the company announced its acquisition by AstraZeneca for circa $150m (USD).

Web: www.arrowt.co.uk

Canbex Therapeutics Ltd

Canbex Therapeutics Ltd. develops compounds for the symptomatic treatment of spasticity in multiple sclerosis, with potential applications in overactive bladder and spinal cord injury. The company has received private investment and translational award funding totalling approximately £0.75m.

Web: www.canbex.co.uk

Canbex Therapeutics

Domainex

In March 2007, NCE Discovery Ltd (NCED), a spin-out from the WIBR, merged with Domainex Ltd (which was established in 2001 by scientists from the Institute of Cancer Research, UCL and Birkbeck College) to form a new drug discovery company. This new company now combines NCED’s expertise in medicinal chemistry and capability in virtual screening (LeadBuilder) with Domainex’s innovative Combinatorial Domain Hunting (CDH) technique for producing recombinant proteins, forming a well-rounded platform for novel drug discovery.

Web: www.domainex.co.uk

Domainex

Inpharmatica

Inpharmatica’s technology applies predictive informatics in biology, medicinal chemistry and ADME (absorption, distribution, metabolism and excretion) to improve the speed and productivity of drug discovery. On December 6, 2006, Galapagos NV, an integrated drug discovery company, acquired Inpharmatica in an all-share transaction valued at €12.5m

Inpharmatica

ProAxon

ProAxon has generated a number of sodium channel blockers that also have a protective effect on neuronal cells and tissues. These neuroprotective compounds have many potential clinical applications, including treatment of neurodegeneration (e.g. glaucoma, multiple sclerosis and Parkinson’s disease), pain, and convulsions (e.g. in epilepsy). The compounds are available for non-exclusive licensing or co-development.

ProAxon


 



Wolfson Institute for Biomedical Research - The Cruciform Building - University College London
Gower Street - London - WC1E 6BT -------------------------- Telephone: +44 (0)20 7679 2000 Copyright © 1999-2008 UCL